Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 4, 2008, Pages 481-486

  Engin, Burhan ^a   Ozdemir M ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Chronic idiopathic urticaria; Dapsone; Randomizedcontrolled trial

Indexed keywords

ANTIHISTAMINIC AGENT; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DAPSONE; DAPSONE FATOL; DESLORATADINE; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHRONIC IDIOPATHIC URTICARIA; CHRONIC URTICARIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTRACUTANEOUS TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DAPSONE; FEMALE; FOLIC ACID ANTAGONISTS; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URTICARIA;

EID: 41149112504     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02510.x     Document Type: Article

References (24)

1. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332: 1767-1772.
2. Grattan CEH, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645-657.
3. Grattan CEH, O'Donnell BF, Francis DM et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143: 365-372.
4. Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA 2 LEN/EDF guideline: Management of urticaria. Allergy 2006; 61: 321-331.
5. Wolf R, Tüzün B, Tüzün Y. Dapsone: Unapproved uses or indications. Clin Dermatol 2000; 18: 37-53.
6. Boehm I, Bauer R, Bieber T. Urticaria treated with dapsone. Allergy 1999; 54: 755-760.
7. Maloff BL, Fox D, Bruin E, Di Meo TM. Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. Eur J Pharmacol 1988; 158: 85-89.
8. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997; 62: 827-836.
9. Cassano N, D'Argento V, Filotico R, Vena GA. Low-dose dapsone in chronic idiopathic urticaria: Preliminary results of an open study. Acta Derm Venereol 2005; 85: 254-255.
10. González P, Soriano V, Caballero T, Niveiro E. Idiopatic angioedema treated with dapsone. Allergol Immunopathol (Madr) 2005; 33: 54-56.
11. Başkan EB, Türker T, Gülten M, Tunali Ş. Lack of correlation between Helicobacter pylori infection and autologous serum skin test in chronic idiopathic urticaria. Int J Dermatol 2005; 44: 993-995.
12. Sabroe RA, Greaves MW. Chronic idiopathic urticaria with functional autoantibodies: 12 years on. Br J Dermatol 2006; 154: 813-819.
13. Nettis E, Dambra P, D'Oronzio L et al. Reactivity to autologous serum skin test and clinical features in chronic idiopathic urticaria. Clin Exp Dermatol 2002; 27: 29-31.
14. Merk HF. Standard treatment. The role of antihistamines. J Invest Dermatol Symp Proc 2001; 6: 153-156.
15. Reimers A, Pichler C, Helbling A, Pichler WJ, Yawalkar N. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32: 1763-1768.
16. Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006; 45: 1224-1227.
17. Juhlin L. Alternative treatments for severely affected patients with urticaria. J Invest Dermatol Symp Proc 2001; 6: 157-159.
18. Stanaland B. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol 2002; 23: 233-241.
19. Tharp MD. Chronic urticaria: Pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98: 325-330.
20. Caproni M, Giomi B, Volpi W et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005; 114: 284-292.
21. Caproni M, Volpi W, Macchia M et al. Infiltrating cells and related cytokines in lesional skin of patients with chronic idiopathic urticaria and positive autologous serum skin test. Exp Dermatol 2003; 12: 621-628.
22. Wozel G, Blasum C, Winter C, Gerlach B. Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: Results of a pilot study. Inflamm Res 1997; 46: 420-422.
23. Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995; 8: 196-202.
24. Gach JE, Sabroe RA, Greaves MW, Kobza Black A. Methotrexate-responsive chronic idiopathic urticaria: A report of two cases. Br J Dermatol 2001; 145: 340-343.